Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
Citação
FRONTIERS IN CARDIOVASCULAR MEDICINE, v.11, article ID 1342832, 9p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction Studies in cholesterol-fed rabbits showed that anti-proliferative chemotherapeutic agents such as paclitaxel associated with solid lipid nanoparticles (LDE) have marked anti-atherosclerotic effects. In addition, association with LDE nearly abolishes paclitaxel toxicity. We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease.Methods We conducted a prospective, randomized, double-blind, placebo-controlled pilot study in patients with multi-vessel chronic coronary artery disease. Patients were randomized to receive IV infusions of LDE-paclitaxel (paclitaxel dose: 175 mg/m2 body surface) or LDE alone (placebo group), administered every 3 weeks for 18 weeks. All participants received guideline-directed medical therapy. Clinical and laboratory safety evaluations were made at baseline and every 3 weeks until the end of the study. Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment.Results Forty patients aged 65.6 +/- 8 years, 20 in LDE-paclitaxel and 20 in placebo group were enrolled. Among those, 58% had diabetes, 50% had myocardial infarction, and 91% were in use of statin and aspirin. Baseline demographics, risk factors, and laboratory results were not different between groups. In all patients, no clinical or laboratory toxicities were observed. From the baseline to the end of follow-up, there was a non-significant trend toward a decrease in IL-6 levels and hsCRP in the LDE-paclitaxel group (-16% and -28%, respectively), not observed in placebo. Regarding plaque progression analysis, variation in plaque parameter values was wide, and no difference between groups was observed.Conclusion In patients with multivessel chronic coronary artery disease and optimized medical therapy, LDE-paclitaxel was safe and showed clues of potential benefits in reducing inflammatory biomarkers.Clinical Trial Registration https://clinicaltrials.gov/study/NCT04148833, identifier (NCT04148833).
Palavras-chave
atherosclerosis, coronary artery disease, nanoparticles, paclitaxel, inflammation, interleukin-6, drug-Related side effects and adverse reactions
URI
https://observatorio.fm.usp.br/handle/OPI/58799
Referências
  1. Azevedo CHM, 2005, GYNECOL ONCOL, V97, P178, DOI 10.1016/j.ygyno.2004.12.015
  2. Bertrand MJ, 2017, EXPERT OPIN EMERG DR, V22, P1, DOI 10.1080/14728214.2017.1269743
  3. de Graaf MA, 2013, INT J CARDIOVAS IMAG, V29, P1177, DOI 10.1007/s10554-013-0194-x
  4. de la Puente P, 2017, EUR J HAEMATOL, V98, P529, DOI 10.1111/ejh.12870
  5. eortc, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
  6. GBD Causes Death Collaborators, 2018, LANCET, V392, P2170, DOI [10.1016/s0140-6736(18)32203-7, 10.1016/S0140-6736(18)32203-7]
  7. Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882
  8. Herder C, 2017, ARTERIOSCL THROM VAS, V37, P1222, DOI 10.1161/ATVBAHA.117.309307
  9. Inoue K, 2010, JACC-CARDIOVASC IMAG, V3, P691, DOI 10.1016/j.jcmg.2010.04.011
  10. Kaptoge S, 2014, EUR HEART J, V35, P578, DOI 10.1093/eurheartj/eht367
  11. Lee SE, 2018, JACC-CARDIOVASC IMAG, V11, P1475, DOI 10.1016/j.jcmg.2018.04.015
  12. Li ZN, 2016, AM HEART J, V180, P29, DOI 10.1016/j.ahj.2016.06.023
  13. Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
  14. Malta DC, 2020, ARQ BRAS CARDIOL, V115, P152, DOI 10.36660/abc.20190867
  15. Maranhao RC, 2008, ATHEROSCLEROSIS, V197, P959, DOI 10.1016/j.atherosclerosis.2007.12.051
  16. Maranhao RC, 2017, EXPERT OPIN DRUG DEL, V14, P1217, DOI 10.1080/17425247.2017.1276560
  17. Maranhao RC, 2015, EXPERT OPIN DRUG DEL, V12, P1135, DOI 10.1517/17425247.2015.999663
  18. Matsumoto S, 2017, CLIN CARDIOL, V40, P210, DOI 10.1002/clc.22646
  19. Naaz F, 2019, EUR J MED CHEM, V171, P310, DOI 10.1016/j.ejmech.2019.03.025
  20. Nakanishi R, 2016, ATHEROSCLEROSIS, V255, P73, DOI 10.1016/j.atherosclerosis.2016.11.004
  21. Novo Nordisk AS, 2025, ZEUS-A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
  22. Papadopoulou SL, 2012, JACC-CARDIOVASC IMAG, V5, pS28, DOI 10.1016/j.jcmg.2012.01.009
  23. Raff Gilbert L, 2009, J Cardiovasc Comput Tomogr, V3, P122, DOI 10.1016/j.jcct.2009.01.001
  24. Ridker PM, 2023, LANCET, V401, P1293, DOI 10.1016/S0140-6736(23)00215-5
  25. Ridker PM, 2021, CIRC RES, V128, P1728, DOI 10.1161/CIRCRESAHA.121.319077
  26. Ridker PM, 2016, CIRC RES, V118, P145, DOI 10.1161/CIRCRESAHA.115.306656
  27. Ridker PM, 2014, EUR HEART J, V35, P1782, DOI 10.1093/eurheartj/ehu203
  28. Ridker PM, 2009, CLIN CHEM, V55, P209, DOI 10.1373/clinchem.2008.119214
  29. ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507
  30. Russell KS, 2019, VASC MED, V24, P414, DOI 10.1177/1358863X19859072
  31. Shiozaki AA, 2016, CLINICS, V71, P435, DOI 10.6061/clinics/2016(08)05
  32. Vaidya K, 2018, JACC-CARDIOVASC IMAG, V11, P305, DOI 10.1016/j.jcmg.2017.08.013
  33. Williams MC, 2020, CIRCULATION, V141, P1452, DOI 10.1161/CIRCULATIONAHA.119.044720

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP